AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24763877 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ablation)
Number of subjects: 110
Study 23047378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 100
Study 23047378 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupet fundoplication
Number of subjects: 100
Study 20926833 — intervention group
Group type: EXPERIMENTAL
Intervention: AIN457 (3 to 10 mg/kg, intravenously)
Number of subjects: 104
Study 20926833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 18540868 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Number of subjects: 111
Study 18540868 — intervention group
Group type: COMPARATOR
Intervention: Group Education (GE)
Number of subjects: 111
Study 15838760 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Sialogogum
Number of subjects: 27
Study 15838760 — intervention group
Group type: COMPARATOR
Intervention: Non-parallel imaging technique
Number of subjects: 27
Study 12466334 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of long-term GH treatment
Number of subjects: 56
Study 10769103 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve root injection of 0.10 g of lidocaine hydrochloride and 3.75 mg of cortivazol
Number of subjects: 30
Study 10769103 — intervention group
Group type: COMPARATOR
Intervention: Interspinous injection of 0.10 g of lidocaine hydrochloride and 3.75 mg of cortivazol
Number of subjects: 30
Study 8991563 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP breathing (10 cm H20 for 25 min)
Number of subjects: 10
Study 8991563 — intervention group
Group type: COMPARATOR
Intervention: BiPAP breathing (10/4 cm H20 for 25 min)
Number of subjects: 10
Study 1728626 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week home-based nutrition education program
Number of subjects: 60
Study 1728626 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 6741440 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 100
Study 6741440 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 100
Study 31130480 — intervention group
Group type: EXPERIMENTAL
Intervention: Early functional rehabilitation (FG)
Number of subjects: 41
Study 31130480 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilization (IG)
Number of subjects: 41
Study 28432193 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (2 mg/kg flunixin meglumine for three consecutive days)
Number of subjects: 154
Study 28432193 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial (6 mg/kg gamithromycin)
Number of subjects: 154
Study 28432193 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (2 mg/kg flunixin meglumine)
Number of subjects: 154
Study 25824185 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial weight-loss programme via GP referral
Number of subjects: 29
Study 25824185 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral by GP and follow-up assessment appointments
Number of subjects: 29
Study 23505169 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day of IQP G‐002AS
Number of subjects: 125
Study 23505169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 21209559 — intervention group
Group type: EXPERIMENTAL
Intervention: Social peer mentoring program (SPM)
Number of subjects: 30
Study 21209559 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 30
Study 18993033 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 164
Study 18993033 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 164
Study 18993033 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 164
Study 18993033 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 164
Study 18993033 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 164
Study 16836598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis and psychosis therapy (CAP)
Number of subjects: 47
Study 16836598 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 47
Study 16836598 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CAP and PE
Number of subjects: 47
Study 14503053 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM group (Chinese drug medication according to patients' syndrome differentiation)
Number of subjects: 120
Study 14503053 — intervention group
Group type: EXPERIMENTAL
Intervention: WM group (chemotherapy)
Number of subjects: 120
Study 14503053 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM-WM group (combined TCM and WM treatment)
Number of subjects: 120
Study 14503053 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TCM-WM group and TCM/WM groups
Number of subjects: 120
Study 11768164 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg DHA
Number of subjects: 120
Study 11768164 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg DHA
Number of subjects: 120
Study 11768164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8996138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus ifosfamide (CIFX)
Number of subjects: 438
Study 8996138 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 438
Study 8996138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus mitolactol (C + M)
Number of subjects: 438
Study 7778797 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ureidopenicillins, cephamycins, and other antibacterial agents active on Gram negative rods and anaerobes) administered as a preoperative flash at anaesthesia induction, followed by a second injection if the procedure duration exceeds 3 hours.
Number of subjects: 0
Study 7778797 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad spectrum antibiotic prophylaxis for extended hysterectomy for cancer.
Number of subjects: 0
Study 7778797 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial prophylaxis in mastectomies.
Number of subjects: 0
Study 2962589 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphonoformate (PFA) intravenous infusion for 3 weeks
Number of subjects: 11
Study 2962589 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 untreated patients)
Number of subjects: 11
Study 2962589 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphonoformate (PFA) intravenous infusion
Number of subjects: 11
Study 2653086 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide via Turbuhaler
Number of subjects: 28
Study 2653086 — intervention group
Group type: COMPARATOR
Intervention: Budesonide via MDI
Number of subjects: 28
Study 30963301 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular pacing through coronary sinus branch
Number of subjects: 60
Study 30963301 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical pacing (control)
Number of subjects: 60
Study 26889691 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training with computer-based visual feedback (BTVF), 4 sessions (2 sessions/day, each session = 15 min)
Number of subjects: 14
Study 26889691 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 14
Study 26149448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Chinese herbal formula (Pei Tu Qing Xin granules; PTQX)
Number of subjects: 124
Study 26149448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 24592780 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-Hz whole-body vibration (WBV)
Number of subjects: 26
Study 24592780 — intervention group
Group type: EXPERIMENTAL
Intervention: 46-Hz whole-body vibration (WBV)
Number of subjects: 26
Study 24592780 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 21677054 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-energy supplements (1015 kcal and 22 g protein/d) provided to pregnant women from 20 weeks gestation until delivery
Number of subjects: 1617
Study 21677054 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g/d) provided to pregnant women from 20 weeks gestation until delivery
Number of subjects: 1617
Study 21677054 — intervention group
Group type: COMPARATOR
Intervention: Lactating women receiving no protein-energy supplements (control group for protein-energy trial)
Number of subjects: 1617
Study 19594505 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 434
Study 19594505 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 434
Study 19594505 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 434
Study 19594505 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone, haloperidol, or placebo
Number of subjects: 434
Study 17447391 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 31
Study 17447391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 16344225 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated O‐15‐labeled CO PET
Number of subjects: 34
Study 16344225 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular magnetic resonance imaging (MRI)
Number of subjects: 34
Study 11182048 — intervention group
Group type: EXPERIMENTAL
Intervention: alphaD3 (1alpha (OH) D3) administered to 18 patients
Number of subjects: 29
Study 11182048 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 patients, untreated)
Number of subjects: 29
Study 11182048 — intervention group
Group type: EXPERIMENTAL
Intervention: alphaD3 (total dose > 1,500 microg)
Number of subjects: 29
Study 9383487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast injection of buffered lidocaine
Number of subjects: 29
Study 9383487 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow injection of buffered lidocaine
Number of subjects: 29
Study 9383487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast injection of unbuffered lidocaine
Number of subjects: 29
Study 9383487 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow injection of unbuffered lidocaine
Number of subjects: 29
Study 7899712 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation (argon green laser, 100-microns spot at 100 mW for 0.1 sec)
Number of subjects: 20
Study 7899712 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 20
Study 3310018 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (2.33 mg daily)
Number of subjects: 100
Study 3310018 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin hydrochloride (115 mg daily)
Number of subjects: 100
Study 3310018 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin hydrochloride
Number of subjects: 100
Study 29185896 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Learning Group (interactive e-learning case-based module)
Number of subjects: 0
Study 29185896 — intervention group
Group type: COMPARATOR
Intervention: Traditional Group (lecture)
Number of subjects: 0
Study 26874076 — intervention group
Group type: EXPERIMENTAL
Intervention: Elafibranor 120 mg
Number of subjects: 276
Study 26874076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 25010237 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone intervention (specific devices not detailed, but included iPhone and BlackBerry)
Number of subjects: 89
Study 25010237 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone intervention
Number of subjects: 89
Study 22105056 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training group (SG)
Number of subjects: 38
Study 22105056 — intervention group
Group type: EXPERIMENTAL
Intervention: Video training group (VG)
Number of subjects: 38
Study 22105056 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 38
Study 20307768 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone trap used to harvest bone debris during implant preparation (group A)
Number of subjects: 61
Study 20307768 — intervention group
Group type: COMPARATOR
Intervention: Bone scraper used to harvest cortical bone chips (group B)
Number of subjects: 61
Study 20307768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 61
Study 18515777 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational medicinal product (statins)
Number of subjects: 84
Study 15956633 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil, 1.8 g/d, 72% omega‐3 PUFAs
Number of subjects: 200
Study 15956633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12525716 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a 30 microg
Number of subjects: 50
Study 12525716 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a 60 microg
Number of subjects: 50
Study 12525716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11407290 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5 MAC) in 67% N2O‐33% O2 and fentanyl + droperidol
Number of subjects: 24
Study 11407290 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (8 mg/kg/h) infusion combined with 67% N2O‐33% O2 and fentanyl + droperidol
Number of subjects: 24
Study 11407290 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 24
Study 11407290 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 24
Study 9297265 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine (Nitroderm NNS 5)
Number of subjects: 61
Study 9297265 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid and curantil
Number of subjects: 61
Study 8427863 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 20
Study 3685881 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 9
Study 3685881 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergics (early postoperative period)
Number of subjects: 9
Study 3685881 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergics (1 year after operation)
Number of subjects: 9
Study 30273622 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prostaglandin analog (latanoprost)
Number of subjects: 350
Study 30273622 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 350
Study 28275100 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-Quantity Lipid-Based Nutrient Supplements (SQ-LNSs; 20 g with 22 micronutrients/d)
Number of subjects: 1320
Study 28275100 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrients (MMNs; 18 vitamins and minerals/d)
Number of subjects: 1320
Study 28275100 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and Folic Acid (IFA; 60 mg Fe + 400 μg folic acid/d)
Number of subjects: 1320
Study 28275100 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo; 200 mg Ca/d)
Number of subjects: 1320
Study 24916605 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Administered Comorbidity Questionnaire (SACQ)
Number of subjects: 300
Study 24916605 — intervention group
Group type: EXPERIMENTAL
Intervention: SACQ-AL (activity-limiting conditions)
Number of subjects: 300
Study 24916605 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 300
Study 24916605 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 300
Study 24916605 — intervention group
Group type: EXPERIMENTAL
Intervention: Back pain
Number of subjects: 300
Study 24004918 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (32 to 35°C)
Number of subjects: 600
Study 20965611 — intervention group
Group type: EXPERIMENTAL
Intervention: Needleless injection device with protection cap (test group)
Number of subjects: 64
Study 20965611 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3‐way stopcock (comparator group)
Number of subjects: 64
Study 19276255 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly bolus irinotecan, 5-fluorouracil, and leucovorin (IFL)
Number of subjects: 1264
Study 19276255 — intervention group
Group type: COMPARATOR
Intervention: Weekly bolus 5-fluorouracil/leucovorin
Number of subjects: 1264
Study 17225709 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 0
Study 17225709 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aortic aneurysm repair
Number of subjects: 0
Study 17225709 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction
Number of subjects: 0
Study 17225709 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty and stenting
Number of subjects: 0
Study 15080782 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma aldosterone concentration (PAC) to active renin concentration (ARC) ratio
Number of subjects: 50
Study 15080782 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma aldosterone concentration (PAC) to active renin concentration (ARC) ratio with PAC > or =200 ng/l
Number of subjects: 50
Study 11306209 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (1 mg/day) combined with dydrogesterone (5, 10 or 20 mg/day)
Number of subjects: 214
Study 9704773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines (interleukin‐1beta and interleukin‐8)
Number of subjects: 2
Study 8058148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezinamide (DZM)
Number of subjects: 15
Study 8058148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2648510 — intervention group
Group type: EXPERIMENTAL
Intervention: Regime A: Rifampicin, Isoniazid, Streptomycin, Pyrazinamide for 2 months followed by Rifampicin and Isoniazid for 4 months (total 6 months treatment)
Number of subjects: 141
Study 2648510 — intervention group
Group type: EXPERIMENTAL
Intervention: Regime B: Rifampicin, Isoniazid, Streptomycin, Pyrazinamide for 2 months followed by Rifampicin and Isoniazid for 5 months (total 9 months treatment)
Number of subjects: 141
Study 2648510 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 141
Study 31065839 — intervention group
Group type: EXPERIMENTAL
Intervention: Information booklet about prostate cancer treatment options prior to biopsy
Number of subjects: 98
Study 31065839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information provided)
Number of subjects: 98
Study 30920186 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude (HA) on day 2
Number of subjects: 17
Study 30920186 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude (HA) on day 7
Number of subjects: 17
Study 30920186 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude (HA) on day 13
Number of subjects: 17
Study 30920186 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude (HA) on day 19
Number of subjects: 17
Study 30920186 — intervention group
Group type: COMPARATOR
Intervention: Model prediction on HA2
Number of subjects: 17
Study 30920186 — intervention group
Group type: COMPARATOR
Intervention: Model prediction on HA7
Number of subjects: 17
Study 30920186 — intervention group
Group type: COMPARATOR
Intervention: Model prediction on HA13
Number of subjects: 17
Study 30920186 — intervention group
Group type: COMPARATOR
Intervention: Model prediction on HA19
Number of subjects: 17
Study 28396144 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) 15 g daily for 12 weeks
Number of subjects: 44
Study 28396144 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 44
Study 26290008 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine meat cooked at 55°C for 5 min
Number of subjects: 16
Study 26290008 — intervention group
Group type: COMPARATOR
Intervention: Bovine meat cooked at 90°C for 30 min
Number of subjects: 16
Study 26290008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cooking methods
Number of subjects: 16
Study 24200404 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 302
Study 24200404 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 280 mg
Number of subjects: 302
Study 24200404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 21629021 — intervention group
Group type: EXPERIMENTAL
Intervention: Victims with mental disorders
Number of subjects: 0
Study 21629021 — intervention group
Group type: COMPARATOR
Intervention: Victims without mental disorders
Number of subjects: 0
Study 19415543 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH); specific dosage and duration not mentioned.
Number of subjects: 0
Study 19415543 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate; specific dosage and duration not mentioned.
Number of subjects: 0
Study 16538619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg alendronate + 1,000 IU vitamin D2
Number of subjects: 288
Study 16538619 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 1,000 IU vitamin D2
Number of subjects: 288
Study 15480128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopically guided bilateral facet injections plus supervised stretching exercises (Group A, n = 36)
Number of subjects: 70
Study 15480128 — intervention group
Group type: COMPARATOR
Intervention: Supervised stretching exercises alone (Group B, n = 34)
Number of subjects: 70
Study 15480128 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 70
Study 11336078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 5.0 mg (1 cc) tid at meal times during radiation
Number of subjects: 60
Study 11336078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9130837 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 97
Study 9130837 — intervention group
Group type: COMPARATOR
Intervention: Long-term medication
Number of subjects: 97
Study 7573830 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine (20 mg/day orally)
Number of subjects: 10
Study 7573830 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 2108835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 25
Study 2108835 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 25